Smart nanoplatform for sequential drug release and enhanced chemo-thermal effect of dual drug loaded gold nanorod vesicles for cancer therapy.
A549 Cells
Animals
Antineoplastic Agents
/ administration & dosage
Apoptosis
/ drug effects
Cell Survival
/ drug effects
Curcumin
/ administration & dosage
Drug Carriers
/ chemistry
Drug Liberation
Gold
/ chemistry
Hep G2 Cells
Humans
Infrared Rays
Integrin alphaVbeta3
/ metabolism
KB Cells
Mice, Inbred BALB C
Nanotubes
/ chemistry
Paclitaxel
/ administration & dosage
Particle Size
Peptides, Cyclic
/ metabolism
Phototherapy
/ methods
Surface Properties
Combination therapy
Dual drug
NIR photothermal effect
Sequential drug release
Stimuli-responsive
Synergistic effect
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
27 Mar 2019
27 Mar 2019
Historique:
received:
20
11
2018
accepted:
09
03
2019
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
12
4
2019
Statut:
epublish
Résumé
The combination of multiple chemotherapeutics has been used in the clinic for enhanced cancer chemotherapy, however, frequent relapse, chemo-resistance and side effects remains therapeutic hurdles. Thus, the development of co-delivery system with enhanced targeting and synergistic different modal treatments has been proposed as promising strategies for intensive improvement of the therapeutic outcomes. We fabricated a nanocarrier based on gold nanorods (Au NRs), cRGD peptide-modified and multi-stimuli-responsive paclitaxel (PTX) and curcumin (CUR) release for synergistic anticancer effect and chemo-photothermal therapy (PTX/CUR/Au NRs@cRGD). The specific banding of cRGD to αvβ3 integrin receptor on the tumor cell surfaces facilitated the endocytosis of PTX/CUR/Au NRs@cRGD, and the near-infrared ray (NIR) further enhanced the drug release and chemotherapeutical efficiency. Compared to single drug, single model treatment or undecorated-PTX/CUR/Au NRs, the PTX/CUR/Au NRs@cRGD with a mild NIR showed significantly enhanced apoptosis and S phase arrest in three cancer cell lines in vitro, and improved drug accumulation in tumor sites as well as tumor growth inhibition in vivo. The tumor targeted chemo-photothermal therapy with the synergistic effect of dual drugs provided a versatile strategy for precise cancer therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The combination of multiple chemotherapeutics has been used in the clinic for enhanced cancer chemotherapy, however, frequent relapse, chemo-resistance and side effects remains therapeutic hurdles. Thus, the development of co-delivery system with enhanced targeting and synergistic different modal treatments has been proposed as promising strategies for intensive improvement of the therapeutic outcomes.
RESULTS
RESULTS
We fabricated a nanocarrier based on gold nanorods (Au NRs), cRGD peptide-modified and multi-stimuli-responsive paclitaxel (PTX) and curcumin (CUR) release for synergistic anticancer effect and chemo-photothermal therapy (PTX/CUR/Au NRs@cRGD). The specific banding of cRGD to αvβ3 integrin receptor on the tumor cell surfaces facilitated the endocytosis of PTX/CUR/Au NRs@cRGD, and the near-infrared ray (NIR) further enhanced the drug release and chemotherapeutical efficiency. Compared to single drug, single model treatment or undecorated-PTX/CUR/Au NRs, the PTX/CUR/Au NRs@cRGD with a mild NIR showed significantly enhanced apoptosis and S phase arrest in three cancer cell lines in vitro, and improved drug accumulation in tumor sites as well as tumor growth inhibition in vivo.
CONCLUSIONS
CONCLUSIONS
The tumor targeted chemo-photothermal therapy with the synergistic effect of dual drugs provided a versatile strategy for precise cancer therapy.
Identifiants
pubmed: 30917812
doi: 10.1186/s12951-019-0473-3
pii: 10.1186/s12951-019-0473-3
pmc: PMC6437988
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Integrin alphaVbeta3
0
Peptides, Cyclic
0
cyclic arginine-glycine-aspartic acid peptide
0
Gold
7440-57-5
Curcumin
IT942ZTH98
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Subventions
Organisme : National Natural Science Foundation of China
ID : 81402854
Organisme : National Key Specialty Construction Project of Clinical Pharmacy
ID : 30305030698
Organisme : President Foundation of Nanfang Hospital, Southern Medical University
ID : 2014033
Références
Eur J Cancer. 2001 Sep;37(13):1590-8
pubmed: 11527683
Int J Pharm. 2002 Mar 20;235(1-2):179-92
pubmed: 11879753
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11613-8
pubmed: 18697944
Chem Soc Rev. 2008 Sep;37(9):1896-908
pubmed: 18762838
Acc Chem Res. 2008 Dec;41(12):1842-51
pubmed: 19053240
Small. 2010 Aug 2;6(15):1669-78
pubmed: 20602428
Adv Mater. 2008 May 5;20(9):1630-1635
pubmed: 21687830
J Pharm Sci. 2011 Dec;100(12):5206-18
pubmed: 21850703
Biomaterials. 2012 Jan;33(3):989-98
pubmed: 22027594
Adv Mater. 2012 Mar 15;24(11):1418-23
pubmed: 22318874
ACS Nano. 2012 Sep 25;6(9):7681-91
pubmed: 22862291
Bioconjug Chem. 2013 Mar 20;24(3):376-86
pubmed: 23360450
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3270-5
pubmed: 23401509
J Am Chem Soc. 2013 Apr 3;135(13):5068-73
pubmed: 23464924
ACS Nano. 2013 Apr 23;7(4):3388-402
pubmed: 23530622
Mol Pharm. 2013 Jul 1;10(7):2676-83
pubmed: 23730903
ACS Nano. 2013 Jul 23;7(7):5858-69
pubmed: 23734880
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10753-8
pubmed: 23754411
Mater Sci Eng C Mater Biol Appl. 2013 Oct;33(7):4094-100
pubmed: 23910319
ACS Nano. 2013 Sep 24;7(9):8089-97
pubmed: 23961973
Arch Pharm Res. 2014 Aug;37(8):1086-95
pubmed: 24318305
Theranostics. 2013 Dec 01;4(1):1-11
pubmed: 24396511
J Am Chem Soc. 2014 Apr 16;136(15):5647-55
pubmed: 24689550
J Am Chem Soc. 2014 May 21;136(20):7317-26
pubmed: 24773323
ACS Nano. 2015 Jan 27;9(1):52-61
pubmed: 25493329
Nanoscale. 2015 Mar 12;7(12):5328-37
pubmed: 25721177
Colloids Surf B Biointerfaces. 2015 Apr 1;128:419-426
pubmed: 25797481
Theranostics. 2015 Apr 20;5(8):818-33
pubmed: 26000055
J Nanobiotechnology. 2015 Aug 28;13:52
pubmed: 26315288
Biomaterials. 2016 Feb;79:25-35
pubmed: 26686979
Biomaterials. 2016 Mar;81:114-124
pubmed: 26731575
ACS Nano. 2016 Mar 22;10(3):3637-47
pubmed: 26905935
Biomacromolecules. 2016 Apr 11;17(4):1253-60
pubmed: 26908114
Nat Mater. 2016 Oct;15(10):1128-38
pubmed: 27454043
Nanoscale. 2016 Nov 10;8(44):18682-18692
pubmed: 27786323
Nanoscale. 2017 Jan 7;9(1):334-340
pubmed: 27922138
ACS Nano. 2016 Nov 22;10(11):10404-10417
pubmed: 27934087
ACS Nano. 2016 Dec 27;10(12):10858-10868
pubmed: 28024382
Nature. 2017 Mar 1;543(7643):40
pubmed: 28252078
J Mater Chem B. 2016 Feb 14;4(6):1150-1155
pubmed: 28261481
ACS Appl Mater Interfaces. 2017 Apr 19;9(15):13037-13048
pubmed: 28338323
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3110-E3118
pubmed: 28356516
ACS Appl Mater Interfaces. 2017 Jun 21;9(24):20361-20375
pubmed: 28532154
Mol Pharm. 2017 Jul 3;14(7):2378-2389
pubmed: 28605595
Nanoscale. 2017 Nov 9;9(43):16661-16673
pubmed: 28809413
Biomaterials. 2017 Dec;147:53-67
pubmed: 28930649
Adv Mater. 2018 Mar;30(11):
pubmed: 29349918
J Nanobiotechnology. 2018 May 31;16(1):50
pubmed: 29855304
Acta Pharm Sin B. 2018 Jul;8(4):587-601
pubmed: 30109183
Biomater Sci. 2018 Oct 24;6(11):2905-2917
pubmed: 30209445